DYNAMICS OF PARAMETERS OF PROINFLAMMATORY ACTIVATION IN PATIENTS WITH HYPERTENSION UNDER INFLUENCE OF CANDESARTAN THERAPY

Aim. Proinflammatory activation is one of the possible pathogenetic mechanisms of formation and progression of hypertension. 107 patients with essential hypertension (EH) II stage was included into the study of the pro-inflammatory activation. Methods and results. Levels of C-reactive protein (CP...

Full description

Bibliographic Details
Published in:	Zaporožskij Medicinskij Žurnal
Main Authors:	V. A. Vizir, A. S. Sadomov, O. V. Goncharov
Format:	Article
Language:	English
Published:	Zaporizhzhia State Medical and Pharmaceutical University 2014-05-01
Subjects:	Hypertension Proinflammatory Activation C-Reactive Protein Soluble Form Of Intercellular Adhesion Molecule-1 Tumor Necrosis Factor-alfa Candesartan
Online Access:	http://zmj.zsmu.edu.ua/article/view/28726/25724

Similar Items

EFFECT OF CANDESARTAN ON PARAMETERS OFDAILYBLOOD PRESSURE IN PATIENTS WITH CHRONIC KIDNEYDISEASE ON HEMODIALYSIS
by: V. A. Vizir, et al.
Published: (2017-12-01)

Candesartan effectiveness in essential arterial hypertension and renal arterial hypertension
by: N. M. Chikhladze, et al.
Published: (2008-12-01)

CANDESARTAN IN CARDIOLOGY PRACTICE
by: N. A. Dzhaiani
Published: (2017-12-01)

Arterial hypertension, cardiovascular remodeling and plasma level of osteopontin in patients with end-stage kidney disease on hemodialysis
by: V. A. Vizir, et al.
Published: (2014-12-01)

The comparison between combination of candesartan-amlodipine and candesartan-furosemide on blood pressure in hypertensive patients with chronic kidney disease
by: Dian Ayu Juwita, et al.
Published: (2022-07-01)

Description of cardiovascular remodeling parameters and osteopontin plasma level in dynamics of the candesartan therapy in patients with chronic kidney disease on the stage before dialysis
by: V. A. Vizir, et al.
Published: (2015-04-01)

Comparative Effects of Candesartan Versus Enalapril on Apelin, Visfatin, and Lipid Levels in Non-obese Hypertensive Patients
by: Yaseen K. JUMAAH, et al.
Published: (2024-09-01)

Genetic variants of GRK4 influence circadian rhythm of blood pressure and response to candesartan in hypertensive patients
by: Nian Cao, et al.
Published: (2021-10-01)

Candesartan cilexetil in cardiovascular prevention
by: A. Ya. Ivleva
Published: (2007-12-01)

LONG-TERM CHANGES OF INFLAMMATION MARKERS IN PATIENTS WITH NON-ST ELEVATION ACUTE CORONARY SYNDROME FOLLOWING CORONARY ARTERY BYPASS GRAFTING SURGERY
by: N. A. Gavricheva, et al.
Published: (2014-08-01)

Optimization and validation of UPLC method for dapagliflozin and candesartan cilexetil in an on-demand formulation: Analytical quality by design approach
by: Elzayat Ehab M., et al.
Published: (2025-07-01)

Identification of Candesartan Cilexetil-L-Arginine Co-amorphous Formation and Its Solubility Test
by: Fikri Alatas, et al.
Published: (2022-02-01)

Comparative evaluation of the impact of candesartan and ramipril therapy on the levels of GDF 15 and NTproBNP, structural and functional performance of the heart in patients with coronary artery disease with asymptomatic diastolic dysfunction after myocar
by: V. D. Syvolap, et al.
Published: (2014-04-01)

COST-EFFECTIVENESS ANALYSIS OF AMLODIPINE AND CANDESARTAN USE IN TYPE 2 DIABETES MELLITUS PATIENTS WITH COMORBID HYPERTENSION IN YOGYAKARTA, INDONESIA
by: Ingenida Hadning, et al.
Published: (2025-08-01)

Cerebroprotective effects of angiotensin II receptor blockers: candesartan focus
by: O. D. Ostroumova, et al.
Published: (2018-09-01)

The limited immunomodulatory effects of escharectomy on the kinetics of endotoxin, cytokines, and adhesion molecules in major burns
by: Tae-Hyung Han, et al.
Published: (2004-01-01)

CHANGES IN THE PROOXIDATIVE-ANTIOXIDANT SYSTEM IN SHR SERIES RATS WITH TREATMENT OF HYPOTENSIVE MEDICINES (RAMIPRIL AND CANDESARTANE) IN COMBINATION WITH CORVITIN
by: Aliona Marushchak, et al.
Published: (2020-07-01)

Technological approaches to improve the bioavailability of the poor soluble substance Candesartan Cilexetil in mini-tablets
by: K. M. Tserkovnaya, et al.
Published: (2025-03-01)

Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats
by: Omar Y. Mady, et al.
Published: (2021-08-01)

Assessment of Soluble Intercellular Adhesion Molecule-1 Based Rapid Test for a Quick Diagnosis of Atypical Prelabor Rupture of Membranes in the Emergency Setting
by: Lin Tang, et al.
Published: (2023-06-01)

Adhesion molecules and cell-cytokine complex in vascular remodeling among patients with arterial hypertension and metabolic risk factors
by: L. R. Iskandarova, et al.
Published: (2008-10-01)

Intoxication with massive doses of amlodipine and candesartan requiring venoarterial extracorporeal membrane oxygenation
by: Minagawa Yusuke, et al.
Published: (2023-01-01)

Effects of 12 Weeks of Endurance Training on Soluble Intercellular Adhesion Molecule-1 (sICAM-1) (Cardiovascular Inflammation Factor) and Lipid Profiles of Elderly Men
by: Ali Akbar Moradi, et al.
Published: (2012-03-01)

Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection
by: Lanlan Xu, et al.
Published: (2021-09-01)

A Functional Analysis on the Interspecies Interaction between Mouse LFA-1 and Human Intercellular Adhesion Molecule-1 at the Cell Level
by: David Núñez, et al.
Published: (2017-12-01)

Achieved dose and treatment discontinuation of candesartan in men and women with chronic heart failure: data from CHARM
by: Hailun Qin, et al.
Published: (2024-08-01)

Determination of candesartan and amlodipine using ion pair and cloud point methods
by: Mohammed Mahmood Abdullah, et al.
Published: (2024-07-01)

Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
by: Marie‐Pierre Dubé, et al.
Published: (2022-10-01)

Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial
by: Takaichi Suehiro, et al.
Published: (2021-03-01)

Dynamics of structural and functional changes of the heart and the levels of GDF 15 and NTproBNP on the candesartan and ramipril therapy in patients with heart failure with preserved ejection fraction after myocardial infarction on the background of arter
by: Ya. V. Zemlyaniy
Published: (2014-04-01)

Clinical Significance of Soluble Intercellular Adhesion Molecule-1 and Interleukin-6 in Patients with Extrahepatic Cholangiocarcinoma
by: Tatsuo Shimura, et al.
Published: (2018-11-01)

Simultaneous Determination of Candesartan and Hydrochlorothiazide in Human Plasma by HPLC-MS/MS
by: P. K. Karnakova, et al.
Published: (2021-11-01)

Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment
by: Moon-Seung Soh, et al.
Published: (2024-10-01)

Candesartan Normalizes Changes in Retinal Blood Flow and p22phox in the Diabetic Rat Retina
by: Randa S. Eshaq, et al.
Published: (2021-03-01)

Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan
by: Musko Monika, et al.
Published: (2014-12-01)

Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool
by: Andrés Figueroa-Campos, et al.
Published: (2020-07-01)

Effects of Nigella sativa on VCAM-1 and ICAM-1: A systematic review of preclinical and clinical studies
by: Zeinab Faghfoori, et al.
Published: (2025-03-01)

The Role of Intercellular Adhesion Molecule-1 in the Pathogenesis of Psychiatric Disorders
by: Norbert Müller
Published: (2019-11-01)

Candesartan: A pharmaceutical product as effective corrosion inhibitor for aluminum in acidic solution
by: Abdel Aziz Fouda, et al.
Published: (2021-09-01)

Functional candesartan loaded lipid nanoparticles for the control of diabetes-associated stroke: In vitro and in vivo studies
by: Dina M. Mahmoud, et al.
Published: (2024-06-01)